Eisai Plans $105-Million Pharma Production and Formulation R&D Facility
Eisai Plans $105 Million Pharma Production and Formulation R&D Facility
Eisai Inc. (Teaneck, NJ, www.eiasi.com), the US pharmaceutical subsidiary of Eisai Co. Ltd. (Tokyo, Japan, www.eisai.co.jp), plans to invest $105 million for a new pharmaceutical production and formulation R&D facility for parenteral oncology treatments in Research Triangle Park, North Carolina.
Of the $105-million capital project, $90 million will be used to build a roughly 65,000-square foot facility that will encompass aseptic processing suites, laboratories, and other support functions. The remaining $15 million will be used to construct a separate central utilities building to supply power, steam, chilled water, and compressed air to existing operations and the new parenteral facility.
Eisai’s existing facility at Research Triangle Park encompasses roughly 190,000 square feet. It is used for the manufacture of “Aricpet” (donepezil) and “Aciphex” (rabeprazole), formulation R&D, and manufacturing of compounds for use in clinical trials.
Groundbreaking for the project is expected in the fall, and operations are expected to begin in 2009.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
